New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced

In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the EULAR presented updated recommendations on the management of PsA [1, 2]. New therapies, assessments and increasing evidence on comorbidities required substantial revision of treatment strategies. This editorial provides comments on the key barriers faced and how these were addressed. The challenges focus around the remit of the recommendations, the scope of the literature review and assessment of the available data.